MAPK7 and melanoma: Lifileucel TIL therapy (11, 13), regorafenib (12), ERK5 inhibitors (14, 15), and targeting CD73 (16) represent other promising avenues to enhance treatment efficacy and manage resistance in advanced melanoma.